Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adamas Pharmaceuticals, Inc.

https://www.adamaspharma.com/

Latest From Adamas Pharmaceuticals, Inc.

Supernus Adds To CNS Portfolio, Especially In Parkinson’s, With Adamas Buyout

Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.

M & A Business Strategies

Keeping Track: Targeted Oncologics Tepmetko, Ukoniq Cleared; Posimir Earns Opioid-Sparing Language

The latest US FDA approval news from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Scrip Asks…What Does 2021 Hold For Biopharma? Part 3: Patient Access To Health Care

Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.

Clinical Trials Coronavirus COVID-19

Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos

Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Other Names / Subsidiaries
    • Osmotica Pharmaceutical US
UsernamePublicRestriction

Register